WHAT YOU NEED TO KNOW
- A Mayo Clinic study examined whether blood levels of p-tau217 can predict cognitive decline within five to 10 years.
- Among people with the same elevated marker level, estimated five year risk was 6% at age 65 and 37% at age 85.
- The blood test may offer a less invasive and more scalable alternative to PET scans for detecting Alzheimer’s related pathology.
- Researchers said the model requires replication and is not ready for routine screening of people without cognitive symptoms.
A blood test that detects a protein linked to Alzheimer’s disease could help estimate whether older adults will develop cognitive decline within five to 10 years. The finding comes from a Mayo Clinic study published in JAMA Neurology.
Researchers examined levels of phosphorylated tau 217, known as p-tau217, in 2,178 adults who had no cognitive impairment. Participants ranged from 60 to 90 years old.
The study also considered each participant’s age, gender and APOE ε4 status. The APOE ε4 genetic variant is associated with Alzheimer’s risk, according to the research.
Participants came from the Mayo Clinic Study of Aging and the Alzheimer's Disease Neuroimaging Initiative. They underwent blood biomarker testing, genetic testing and multiple cognitive assessments.
MORE NEWS: Mexico’s Flying ‘Pterodactyl’ Videos Get a Brutal Reality Check from a Palaeontologist [WATCH]
After researchers accounted for p-tau217, APOE ε4 had a modest association with risk. Older age, however, was associated with a greater risk of cognitive impairment.
The researchers illustrated that difference using people with the same elevated p-tau217 level. A 65 year old had an estimated 6% risk of mild cognitive impairment over five years, compared with 37% for an 85 year old.
Alzheimer’s disease is marked by plaques and tangles that accumulate in the brain, according to senior author Clifford Jack Jr., a Mayo Clinic neuroradiologist. The blood test is intended to detect evidence of that pathology through a blood sample.
"The test tells you, just by taking a blood sample, whether someone has that pathology in the brain," Jack told Fox News Digital. He added that higher levels of the pathology are associated with a greater risk of progressing from normal cognition to impairment.
Detecting p-tau217 in blood may be less invasive and potentially more scalable than using PET scans to measure amyloid burden. Amyloid burden is a hallmark of Alzheimer’s disease associated with future cognitive impairment.
"The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology," first author Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher, said in a news release.
The test could become more significant if investigational treatments are found to prevent or delay cognitive decline. Its potential role would be to help translate biomarker results into an individualized estimate of future risk.
"If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment," Jack noted.
The study also carries important limitations. Its risk estimates were developed through the Mayo Clinic Study of Aging, which draws participants from a specific geographical area.
"The older population in southeast Minnesota is not representative of the entire United States," Jack said. Although the study’s methods could be applied to other populations, he said the findings must be replicated outside the region.
The prediction model is not ready for routine screening among people without cognitive symptoms, according to the research team. "There is no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain," Jack told Fox News Digital.
Jack said the test results currently would not change medical management because no treatment is available for people in that situation. That could change if preventive treatments receive approval.
The study does not establish that routine blood testing prevents dementia or improves clinical outcomes. It also does not mean everyone with Alzheimer’s related pathology will eventually experience cognitive impairment.
"Many elderly people who have the pathology in the brain at lower levels will never develop symptoms in their lifetime," Jack added. Some people with Alzheimer’s related pathology may also die from another cause before cognitive impairment develops.
Join the Discussion
COMMENTS POLICY: We have no tolerance for messages of violence, racism, vulgarity, obscenity or other such discourteous behavior. Thank you for contributing to a respectful and useful online dialogue.